Traws Pharma (NASDAQ:TRAW) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Traws Pharma (NASDAQ:TRAW) announced its earnings results on Friday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.03, FiscalAI reports.

Traws Pharma Stock Performance

Shares of NASDAQ:TRAW traded up $0.25 during midday trading on Friday, hitting $1.88. The company’s stock had a trading volume of 1,927,070 shares, compared to its average volume of 6,174,927. The business’s 50 day simple moving average is $1.68 and its 200 day simple moving average is $1.86. The company has a market cap of $19.10 million, a P/E ratio of 1.75 and a beta of 1.47. Traws Pharma has a 12-month low of $0.99 and a 12-month high of $3.27.

Insider Buying and Selling at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were purchased at an average cost of $1.67 per share, with a total value of $998,207.43. Following the completion of the purchase, the insider owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 14.00% of the company’s stock.

Hedge Funds Weigh In On Traws Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd lifted its stake in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after buying an additional 31,502 shares in the last quarter. Ikarian Capital LLC lifted its stake in shares of Traws Pharma by 2,280.0% in the fourth quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after buying an additional 649,649 shares in the last quarter. Squadron Capital Management LLC purchased a new position in shares of Traws Pharma in the fourth quarter worth about $806,000. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma in the fourth quarter worth about $220,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Traws Pharma in the fourth quarter worth about $175,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TRAW has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Traws Pharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Friday, May 1st. LADENBURG THALM/SH SH upgraded shares of Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.